The Verkhovna Rada of Ukraine has approved a National Tuberculosis Control Program for 2012-2016.  

Cape Town — The government's massive scaling up of its anti-retroviral (ARV) treatment programme is beginning to show results, with a new report showing that South Africa's life expectancy has increased by over three years in the last two years.

WHO/Europe has established the European Tuberculosis Laboratory Initiative (ELI) to increase laboratory capacity to diagnose multidrug- and extensively drug-resistant tuberculosis (M/XDR-TB) across WHO European Region, as part of a consolidated action plan for 2011–2015.

18 October 2012 – Geneva – The new data published in the WHO Global Tuberculosis Report 2012 show clear signs of progress.

Among patients with extensively drug-resistant (XDR) tuberculosis, adding linezolid (Zyvox) to standard therapies appears to improve treatment response, but with a high rate of adverse events, a phase IIb trial showed.

An intensive, high-level course on TB diagnostic research methods.

Citizen News Service (CNS) and the global Stop-TB eForum along with partners are hosting an online consultation to document community perspectives and learn lessons on what worked and what didn’t in rolling out MDR-TB services in different countries/ contexts. These lessons are very important, especially experiences of affected communities, we believe, and must not be missed. These lessons should inform the ongoing and future planned roll-out (and scale up) of MDR-TB services at all levels.

NEW YORK, NY/GENEVA, SWITZERLAND – A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance trends around the globe.

WHO warns global fight against TB now at a crossroads; Only 1 in 5 patients with multidrug resistant TB diagnosed; US$ 3 billion annual funding shortfall for epidemic response.

Brussels/Lausanne/Zaragoza/Lelystad, 16 October 2012 – European scientists are one step closer to delivering a new, safe and more effective vaccine against tuberculosis. Swiss-medic, the Swiss regulatory authority for medicine has given permission to start assessing the new TB vaccine in healthy adult volunteers. The vaccine, called MTBVAC, is the first vaccine of its kind to start clinical evaluation.